<img alt="" height="1" width="1" />News and FDA Updates for Salix (NASDAQ:SLXP), Enzo (NYSE:ENZ), Lannett (NYSE:LCI)American Chronicle... the Company´s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). ...<nobr>and more »</nobr> |